MTOR

Galectin Therapeutics Update on the Impact of COVID-19

Thursday, April 2, 2020 - 1:04pm

NORCROSS, Ga., April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities.

Key Points: 
  • NORCROSS, Ga., April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities.
  • Galectin Therapeutics Inc. has developed several overarching principles to guide its conduct of clinical research in light of COVID-19.
  • Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.
  • Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor GR-MD-02

Bioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in Patients

Tuesday, March 31, 2020 - 12:00pm

Over the past decade there has been a strong body of evidence that indicates that Galectin-1 is implicated in viral pathogenesis.

Key Points: 
  • Over the past decade there has been a strong body of evidence that indicates that Galectin-1 is implicated in viral pathogenesis.
  • This galectin-1 treatment resulted in a survival benefit of the mice and indicated theoretical mechanisms of action (MOA) in humans.
  • The SARS virus has a galectin fold which in theory represents a binding spot on the virus for Bioxytrans galectin-1 inhibitor.
  • The journal articles provide a strong foundation that galectin-1 is implicated in COVID-19, said CEO David Platt of Bioxytran Inc. and co-author of Galectin.

DGAP-News: Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway

Thursday, March 26, 2020 - 8:01am

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication

Key Points: 
  • DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication
    Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway
    The issuer is solely responsible for the content of this announcement.
  • Both targets are catalytic enzymes that play a key role in an important immunosuppressive pathway - the degradation of tryptophan into kynurenine.
  • Secarna's approach also was shown to be synergistic with one of the clinically most advanced IDO1-specific small molecule inhibitors (epacadostat).
  • The published data show that treatment of cancer cells with LNAplusTM-modified ASOs specific for IDO1 and TDO2 lead to potent target knockdown in vitro.

Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome

Wednesday, March 11, 2020 - 12:01pm

Based upon the written response from the EMA, Seelos will design an open-label, non-placebo controlled,Phase IIb/III pivotal study for the treatment of patients with Sanfilippo syndrome types A and B in the European Union (EU).

Key Points: 
  • Based upon the written response from the EMA, Seelos will design an open-label, non-placebo controlled,Phase IIb/III pivotal study for the treatment of patients with Sanfilippo syndrome types A and B in the European Union (EU).
  • The EMAs recommendation to use appropriate natural history data of Sanfilippo syndrome patients allows us to offer active therapy to all children enrolled in the study, said Raj Mehra, Ph.D., Chairman and CEO of Seelos.
  • This devastating disease currently lacks any approved treatment and we look forward to taking this next step in advancing our SLS-005 program.
  • Trehalose activates autophagy through the activation of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression.

Sirolimus Market Insights 2020-2025: Anticipating a CAGR of 4.1%, Worldwide

Tuesday, March 10, 2020 - 3:45pm

DUBLIN, March 10, 2020 /PRNewswire/ -- The "Sirolimus Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 10, 2020 /PRNewswire/ -- The "Sirolimus Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The Sirolimus Market is expected to register a CAGR of 4.1% during the forecast period.
  • As Sirolimus targets mTOR which involve in various critical biological functions, and it has many treatment applications beyond organ transplantation.
  • Increasing transplantation rates and occurrence of lifestyle-related diseases, promising pipeline for different indications and improving healthcare infrastructure are the key driving factors of sirolimus market.

Meritor's Plainfield, Indiana Site Recognized in 2020 Governor's Workplace Safety Awards

Monday, March 9, 2020 - 8:15pm

TROY, Mich., March 9, 2020 /PRNewswire/ --Meritor, Inc. (NYSE: MTOR) today announced its Plainfield, Indiana site has earned the Rising Star recognition in the 2020 Governor's Workplace Safety Awards for positively impacting employee safety and demonstrating proactive measures to improve the plant's safety and health culture.

Key Points: 
  • TROY, Mich., March 9, 2020 /PRNewswire/ --Meritor, Inc. (NYSE: MTOR) today announced its Plainfield, Indiana site has earned the Rising Star recognition in the 2020 Governor's Workplace Safety Awards for positively impacting employee safety and demonstrating proactive measures to improve the plant's safety and health culture.
  • The site, which placed renewed focus on safety in 2016, has not had a recordable injury since 2018.
  • The annual Governor's Workplace Safety Awards are a joint initiative among government, business and safety leaders including the Indiana Department of Labor on behalf of Gov.
  • Eric J. Holcomb, the Indiana Chamber of Commerce and the Central Indiana Chapter of the American Society of Safety Engineers.

Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita

Friday, March 6, 2020 - 12:00pm

VALO is a multi-center, four-part, Phase 2/3 study evaluating the safety and effectiveness of PTX-022 in adults with PC.

Key Points: 
  • VALO is a multi-center, four-part, Phase 2/3 study evaluating the safety and effectiveness of PTX-022 in adults with PC.
  • Palvella also intends to initiate an open-label extension program where patients will have the option to continue to receive study drug.
  • PTX-022 is supported by multiple issued method-of-use patents in the U.S. broadly covering the use of mTOR inhibitors in pachyonychia congenita.
  • Palvellas lead program, PTX-022 (QTORIN 3.9% rapamycin anhydrous gel), is in Phase 2/3 development for pachyonychia congenita, a rare, chronically debilitating and lifelong genetic disease.

BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930

Thursday, March 5, 2020 - 12:00pm

BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases.

Key Points: 
  • BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases.
  • The company expects to report data from the proof of concept study in PNH patients in the second quarter of 2020.
  • Because Factor D is essential for alternative pathway overactivity in PNH, and all other complement diseases of the alternative pathway, successful proof of concept data with BCX9930 would enable BioCryst to advance the program across other target indications.
  • In this proof of concept study of the safety and effectiveness of oral BCX9930, up to 16 PNH patients will receive BCX9930 twice daily (BID) for 28 days.

Seurat Therapeutics Announces Novel Mechanisms from Rat Migraine Model of Intranasal Insulin-like Growth Factor-1

Monday, February 10, 2020 - 6:45pm

Seurat Therapeutics, Inc. (Seurat) announced today the publication of preclinical studies of its lead product candidate, intranasal insulin-like growth factor-1 (IGF-1), in a rat model of migraine headaches, in the scientific journal Brain Research.

Key Points: 
  • Seurat Therapeutics, Inc. (Seurat) announced today the publication of preclinical studies of its lead product candidate, intranasal insulin-like growth factor-1 (IGF-1), in a rat model of migraine headaches, in the scientific journal Brain Research.
  • Seurat is the world-wide licensee of patents for nasal IGF-1 treatment of migraine headaches from the University of Chicago.
  • The publication reports that trigeminal pain pathway activation is significantly reduced after intranasal IGF-1 treatment.
  • These findings support that intranasal IGF-1 has a unique potential to safely prevent migraine headaches through multiple novel mechanisms.

eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types

Thursday, January 9, 2020 - 1:00pm

eIF4E is an effector protein that is activated in a variety of human cancers and is linked to poor prognosis and resistance to certain therapies.

Key Points: 
  • eIF4E is an effector protein that is activated in a variety of human cancers and is linked to poor prognosis and resistance to certain therapies.
  • Under terms of the agreement, eFFECTOR will receive a $15 million payment upfront, and will be eligible for additional potential $492M in R&D funding, development and sales milestone payments.
  • It will leverage our collective development capabilities and Pfizers global commercial resources to build momentum around eIF4E inhibitor development and maximize the potential impact for cancer patients.
  • eFFECTORs most advanced program, tomivosertib (eFT508), is currently in Phase 2 clinical trials for the treatment of several types of cancer.